Table 1.
Characteristics of newly diagnosed localized prostate cancer cases by year of diagnosis, SEER-Medicare, 2004–2015
| 2004–2005a | 2006–2007 | 2008–2009 | 2010–2011 | 2012–2013 | 2014–2015 | Total | |
|---|---|---|---|---|---|---|---|
| (N = 36,244) | (N = 36,827) | (N = 31,424) | (N = 29,048) | (N = 22,680) | (N = 22,074) | (N = 178,297) | |
|
| |||||||
| GS≤6a | 17,313 (47.8) | 16,240 (44.1) | 12,959 (41.2) | 11,558 (39.8) | 8,276 (36.5) | 7,089 (32.1) | 73,435 (41.2) |
| GS≥7 | 18,931 (52.2) | 20,587 (55.9) | 18,465 (58.8) | 17,490 (60.2) | 14,404 (63.5) | 14,985 (67.9) | 104,862 (58.8) |
| Age 66–74 | 19,413 (53.6) | 20,211 (54.9) | 18,483 (58.8) | 17,479 (60.2) | 14,239 (62.8) | 14,067 (63.7) | 103,892 (58.3) |
| Age 75–110 | 16,831 (46.4) | 16,616 (45.1) | 12,941 (41.2) | 11,569 (39.8) | 8,441 (37.2) | 8,007 (36.3) | 74,405 (41.7) |
| Non-Hispanic Black | 4,132 (11.4) | 3,884 (10.5) | 3,453 (11) | 3,203 (11) | 2,598 (11.5) | 2,346 (10.6) | 19,616 (11) |
| Non-Hispanic White | 29,771 (82.1) | 30,538 (82.9) | 25,838 (82.2) | 23,866 (82.2) | 18,476 (81.5) | 18,020 (81.6) | 146,509 (82.2) |
| Other Race/ethnicity | 2,341 (6.5) | 2,405 (6.5) | 2,133 (6.8) | 1,979 (6.8) | 1,606 (7.1) | 1,708 (7.7) | 12,172 (6.8) |
| Comorbidity = 0 | 21,367 (59) | 21,335 (57.9) | 17,593 (56) | 15,832 (54.5) | 12,130 (53.5) | 12,327 (55.8) | 100,584 (56.4) |
| Comorbidity > 0 and <3 | 10,463 (28.9) | 11,081 (30.1) | 9,917 (31.6) | 9,445 (32.5) | 7,379 (32.5) | 6,640 (30.1) | 54,925 (30.8) |
| Comorbidity ≥3 | 3,041 (8.4) | 3,099 (8.4) | 2,845 (9.1) | 2,768 (9.5) | 2,207 (9.7) | 1,898 (8.6) | 15,858 (8.9) |
| Comorbidity unknown | 1,373 (3.8) | 1,312 (3.6) | 1,069 (3.4) | 1,003 (3.5) | 964 (4.3) | 1,209 (5.5) | 6,930 (3.9) |
| Rural | 3,999 (11) | 4,015 (10.9) | 3,322 (10.6) | 3,000 (10.3) | 2,249 (9.9) | 2,235 (10.1) | 18,820 (10.6) |
| Urban | 32,205 (88.9) | 32,775 (89) | 28,044 (89.2) | 26,001 (89.5) | 20,394 (89.9) | 19,797 (89.7) | 159,216 (89.3) |
| Rural/urban unknown | 40 (0.1) | 37 (0.1) | 58 (0.2) | 47 (0.2) | 37 (0.2) | 42 (0.2) | 261 (0.1) |
| Not Medicaid | 33,208 (91.6) | 33,937 (92.2) | 28,872 (91.9) | 26,755 (92.1) | 20,973 (92.5) | 20,591 (93.3) | 164,336 (92.2) |
| Medicaid | 3,036 (8.4) | 2,890 (7.8) | 2,552 (8.1) | 2,293 (7.9) | 1,707 (7.5) | 1,483 (6.7) | 13,961 (7.8) |
| SES lowb | 12,207 (33.7) | 11,756 (31.9) | 10,023 (31.9) | 9,146 (31.5) | 6,920 (30.5) | 6,350 (28.8) | 56,402 (31.6) |
| SES medium | 11,860 (32.7) | 12,269 (33.3) | 10,455 (33.3) | 9,491 (32.7) | 7,483 (33) | 7,299 (33.1) | 58,857 (33) |
| SES high | 11,376 (31.4) | 11,967 (32.5) | 10,257 (32.6) | 9,732 (33.5) | 7,781 (34.3) | 7,897 (35.8) | 59,010 (33.1) |
| SES unknown | 801 (2.2) | 835 (2.3) | 689 (2.2) | 679 (2.3) | 496 (2.2) | 528 (2.4) | 4,028 (2.3) |
| Southc | 8,798 (24.3) | 9,216 (25) | 8,101 (25.8) | 7,404 (25.5) | 5,964 (26.3) | 5,711 (25.9) | 45,194 (25.3) |
| North central | 4,704 (13) | 4,488 (12.2) | 3,769 (12) | 3,576 (12.3) | 2,682 (11.8) | 2,545 (11.5) | 21,764 (12.2) |
| Northeast | 7,118 (19.6) | 7,640 (20.7) | 6,264 (19.9) | 5,754 (19.8) | 4,445 (19.6) | 4,372 (19.8) | 35,593 (20) |
| Pacific/West | 15,624 (43.1) | 15,483 (42) | 13,290 (42.3) | 12,314 (42.4) | 9,589 (42.3) | 9,446 (42.8) | 75,746 (42.5) |
a
Column percentage in parentheses; and GS = Gleason score. For GS, we used the Gleason score from needle core biopsy/transurethral resection of prostate (TURP)
b
SES for social and economic status
c
South: Atlanta, Rural Georgia, KY, LA, GA; North Central: Detroit, Iowa; Northeast: CT, NJ; Pacific/West: San Francisco, Hawaii, New Mexico, Seattle, Utah, Alaska, San Jose, Los Angeles, CA.